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A B S T R A C T   
Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial 
contributors to morbidity and mortality across Europe. Much of these diseases burden is modifiable, in particular 
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by lipid-lowering therapy (LLT). Current guidelines are based on the sound premise that with respect to low 
density lipoprotein cholesterol (LDL-C), “lower is better for longer”, and the recent data have strongly emphasized 
the need of also “the earlier the better”. In addition to statins, which have been available for several decades, the 
availability of ezetimibe and inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) are additional 
very effective approach to LLT, especially for those at very high and extremely high cardiovascular risk. LLT is 
initiated as a response to an individual’s calculated risk of future ASCVD and is intensified over time in order to 
meet treatment goals. However, in real-life clinical practice goals are not met in a substantial proportion of 
patients. This Position Paper complements existing guidelines on the management of lipids in patients following 
ACS. Bearing in mind the very high risk of further events in ACS, we propose practical solutions focusing on 
immediate combination therapy in strict clinical scenarios, to improve access and adherence to LLT in these 
patients. We also define an ‘Extremely High Risk’ group of individuals following ACS, completing the attempt 
made in the recent European guidelines, and suggest mechanisms to urgently address lipid-medicated cardio-
vascular risk in these patients.   
1. Introduction 
Atherosclerotic cardiovascular disease (ASCVD), results in myocar-
dial ischaemia, and is a substantial contributor to morbidity and mor-
tality across Europe and worldwide [1]. In 2017, about 34.9 million 
people were estimated to live with ischaemic heart disease (IHD) in 54 
European Society of Cardiology (ESC) member countries, resulting in an 
estimated cost of €59 billion in 2015 [2]. The median number of 
age-standardized disability adjusted life-years (DALYs) due to CVD, was 
4530 per 100,000 inhabitants of ESC member countries, of which 54% 
were attributable to IHD [2]. The European Association of Percutaneous 
Cardiovascular Interventions (EAPCI) have reported an annual median 
of 2478 percutaneous coronary intervention (PCI) procedures per 
million people [3]. Much of this disease burden is modifiable, in 
particular by lipid-lowering therapy (LLT) [4,5]. In addition, to statins 
and ezetimibe, the availability of proprotein convertase subtilisin/kexin 
type 9 inhibitors (PCSK9is) presents an additional opportunity to reduce 
the risk of ASCVD. These new agents are more expensive than other 
LLTs, and therefore should be prioritised for use in those patients who 
are most likely to benefit from them. These are particularly patients at 
very high risk of ASCVD, including many who have already experienced 
an acute coronary syndrome (ACS) [6,7]. 
Multiple sources of evidence demonstrate that an individual’s life-
time exposure to low density lipoprotein cholesterol (LDL-C) determines 
their risk of ASCVD [4,8]. In patients who have had a myocardial 
infarction, poor adherence to statin therapy is common, and is associ-
ated with worse outcomes [9,10], attainment of treatment targets is 
poor [11], and higher-intensity LLT results in fewer ASCVD events than 
less-intensive treatment [12,13]. Whilst primary prevention uses pre-
diction tools such as Systematic COronary Risk Evaluation (SCORE) to 
grade risk [14], post ACS patients are categorised as ‘very high risk’ in 
current ESC/European Atherosclerosis Society (EAS) dyslipidaemia 
guidelines [15], although they are in fact a heterogeneous group, in 
which risk factors can be used to identify those individuals at more than 
the highest risk of further ASCVD events [16]. Those individuals with 
the highest absolute risk, are likely to receive the largest benefit from the 
innovative treatment with PCSK9 inhibitors [5]. 
Taking these facts into account, there is an urgent need to ensure that 
guideline-directed LLT is prescribed to all ACS patients, and to ensure 
that those individuals at greatest risk of recurrent events can access the 
most efficacious LLT without delay, thereby reducing their exposure to 
elevated LDL-C. It is especially important as the recent ESC/EAS 
guidelines in many places are more academic than clinical, and in many 
countries it is not possible to be on target < 55 mg/dl (1.4 mmol/l) for 
very high risk and < 40 (1.0 mmol/l) for the extremely high risk patients 
not due to lack of knowledge or nonadherence, but simply due to lack of 
availability of effective LLT. In many countries of Central and Southern 
Europe (represented by the experts in this Position Paper) not only are 
PCSK9 inhibitors limited and reimbursed only for very selected groups 
of patients, but even the availability of all statins and ezetimibe is 
sometimes limited and e.g., can be prescribed only by the specialists and 
without co-payment only for selected indications. These are arguments 
for giving an opportunity for much more ACS patients to achieve LDL-C 
target but also it is a loud call-for-action to support the experts in those 
countries in their negotiations with the healthcare providers and in-
surers to allow them to use all available therapies for those patients. 
2. Guideline context 
The use of LLT in ACS is covered in the 2019 ESC/EAS guidelines for 
the management of dyslipidaemias [15], a wide-ranging document, 
which deals with a range of primary and secondary prevention sce-
narios. The guidelines are based on sound principles of LDL-C reduction: 
the earlier the better, the lower the better, the longer the better [17,18], 
and strong recommendation for cardiac rehabilitation programmes [15, 
19,20]. The importance and benefit of early access to statin therapy is 
highlighted [14,21–23]. The guidelines recommend intensification of 
statin therapy and addition of ezetimibe, if treatment targets are not met 
(Class IIa) [15]. Furthermore, if the LDL-C goal is not achieved after 4–6 
weeks despite maximally tolerated statin therapy and ezetimibe, addi-
tion of a PCSK9 inhibitor is recommended (Class 1) [15]. These guide-
lines for the first time also suggested the possibility of introduction of 
PCSK9 inhibitors for ACS patients during hospitalization (Class IIa). 
However due to the reimbursement criteria in most countries, this 
recommendation is simply not applicable. 
Nevertheless, this incremental approach of adding drugs after failing 
to meet targets does not allow for the fact that the proportional lipid 
reduction achievable with current treatments is predictable [15], and in 
many cases with very high baseline LDL-C, monotherapy is extremely 
unlikely to enable patients to reach their treatment targets [24–26]. This 
results in delay to target attainment and unnecessary further exposure to 
LDL-C. Furthermore, the guidelines treat all ACS patients (“Documented 
ASCVD, either clinical or unequivocal on imaging. Documented ASCVD in-
cludes previous ACS (MI or unstable angina), stable angina, coronary 
revascularization (PCI, CABG, and other arterial revascularization proced-
ures), stroke and TIA, and peripheral arterial disease.) as ‘very high risk’, 
without allowing for variability within this group [15]. 
There is therefore a strong argument to initiate therapy with multiple 
drugs (double or even triple therapy) immediately during hospitaliza-
tion or during the visit, in the highest-risk patients - an approach which 
is already used in the management of hypertension [24–27]. 
3. Overarching aim 
This Position Paper complements existing guidelines on the man-
agement of lipids in patients after ACS. Bearing in mind the very high 
risk of further events in patients with ACS, we propose practical ap-
proaches to improve access and adherence to LLT in these patients. We 
also adopt the definition of an ‘Extremely High Risk’ group of individuals 
following ACS and suggest strategies to urgently address lipid- 
medication of cardiovascular risk in these patients. The Position Paper 
is based entirely on evidence relating to the clinical effectiveness of 




Summary of current approaches to LLT and challenges in participating countries. 1. Availability of ACS registry; 2. Availability of special guidelines on how to manage ACS patients; 2. Statin availability (free to all, free but 
only in the special clinical scenarios, not available like in Bosnia, etc.); 3. Ezetimibe availability (as above, with the clear information on who might prescribe this); 4. PCSK9 inhibitors restrictions; 5. Unmet needs/gaps; 6. 





Statin availability Ezetimibe availability PCSK9I availability Unmet Needs Educational/Critical Needs 
Initiation Co- 
paymenta 





NO NO GPs & 
Specialists 
YES (60%) NO Specialist Fully paid (no 
reimbursement) 
NO Not reimbursed (may 
become available for 




presciption of high- 
intensity statins 
Ensuring LDL-C goal and 
expected actions are well 
understood by presribers and 
clearly communicated in 




NO NO Specialist YES (50%) YES Specialist YES (no 
reimbursement) 
YES 
Croatia YES YES GPs & 
Specialists 
NO YES Specialists NO YES Initiation restricted to 
specialists 
Consistent achievement 
of LDL-C target 
Education for GPs and patients 
regarding targets 
ACS (with max statin +
EZE) 
HeFHNo co-payment 
Czech Republic YES YES GPs & 
Specialists 
NO NO GPs & 
Specialists 
NO NO Reimbursement restricted 
to specialist centres (LDL-C 
>2.5 mmol/L with max 
statin plus EZE) 
Follow-up referrals for 
optimal lipid 
management 
Continuous education at all 
levels 
Greece NO YES GPs & 
Specialists 
YES (small) NO GPs & 
Specialists 
YES (small) NO Initiation restricted to 
specialists 
Need for consistent 
approach 
Dissemination of national 
consensus paper 
Secondary prevention, 
primary in FH (with LDL 
targets unmet) 
No co-payment 




NO Specialists YES (max €2/ 
month) 
YES Initiation restricted to 
specialists 
Ensuring LDL-C is 
measured for all 
patients during index 
hospitalisation 
Ensuring LDL-Goal is 
communicated in discharge 
letter Approval on named- 
patient basis Improve patient knowledge 
regarding importance of LDL-C 
reduction 
Post-ACS (with max statin 
and EZE and unmet LDL-C 
targets) 
Co-payment: (€7/ month) Structured follow-up of 
patients by cardiologist 
and GPs 
Poland YES YES GPs & 
Specialists 
Yes (small) NO GPs & 
Specialists 
Yes (small) NO Initiation restricted to 
specialists 
Increase proportion of 
patients referred to 
comprehensive care 
programme 
National and local education 
campaigns for doctors 
FH (with additional 
restrictions) 
Very high/extreme risk 
after AMI (with additional 
restrictions) 
Romania NO YES GPs & 
Specialists 
YES (10%) NO Specialists 50% YES Initiation restricted to 
specialists 
Ensuring LDL-C is 
measured for all 
patients during index 
hospitalisation 
Ensuring LDL-Goal is 
communicated in discharge 
letter Eligibility based upon 
current lipid-lowering 
therapy and unlet LDL-c 
targets 
Consistent achievement 
of LDL-C target 
Improve patient knowledge 
regarding importance of LDL-C 
reduction Fully reimbursed 
Slovakia YES YES GPs & 
Specialists 
YES (small) NO Specialists YES (small) YES Initiation restricted to 
specialists 
Therapeutic inertia 
(continued on next page) 
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Statin availability Ezetimibe availability PCSK9I availability Unmet Needs Educational/Critical Needs 
Initiation Co- 
paymenta 
Restrictionsb Initiation Co-paymenta Restrictionsb 
Patient education to counter 
misinformation and improve 
adherence 
Treatment must be 
approved in advance by 
insurance company 
Restricted to defined 
patient population with 
very high LDL-C threshold 
Fully reimbursed 





NO GPs & 
Specialists 
YES YES Initiation restricted to 
specialists 
Standard pathway for 
ACS 
Educational needs for patients 
2º prevention (with max 
statin and EZE) 
National survey (for quality 
control) 
1º prevention (HeFH) 
Statin intolerance (2 
statins) 
Fully reimbursed (No co- 
payment within 
restrictions) 
Patients followed in PCSK9 
registry 
Abbreviations: AMI, Acute Myocardial Infarction; EZE, Ezetimibe; HeFH, heterozygous familial hypercholesterolaemia; NA, not applicable. 
a Is co-payment necessary when drugs are prescribed within restrictions. 
b Is reimbursement restricted to specific patient groups. 
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Fig. 1. Overall pathway of optimal lipid-lowering therapy post-acute coronary syndrome (ACS). The pathway is divided into three Stages: (1) Diagnosis and 
stratification, (2) Target-driven lipid-lowering therapy, (3) Support and follow-up. Special pathways are provided for specific treatment groups including those with 
extreme cardiovascular (CV) risk (as defined in this document), familial hypercholesterolaemia, statin intolerance or elevated LDL-C despite dual therapy with 
maximally tolerated statin and ezetimibe. 
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LLTs, rather than pharmacoeconomic evaluations. 
4. Development of Position Paper 
The ACS EuroPath Central & South European Countries Project 
started with a videoconference meeting in June 2020 between members 
of the Steering Committee (comprised of International Lipid Expert 
Panel members), and representatives from Bosnia & Herzegovina, 
Croatia, Czech Republic, Greece, Hungary, Poland, Romania, Slovakia 
and Slovenia who discussed current clinical practice, including avail-
ability of hypolipidemic drugs, data gathering (ACS registries), organi-
zation of healthcare systems as a way to understand unmet needs, 
identification of post ACS patients most in need for LLT intensification, 
and strategies for optimal lipid management. In a second (December 
2020) videoconference, representatives from each country gave an up-
date of lipid-lowering practice in their region, with a particular focus on 
areas for improvement. Members of the steering committee summarized 
the information and presented draft practice recommendations, which 
could be universally applicable in all states. These recommendations 
were discussed during the videoconference. All participants were also 
able to engage in online discussion via a web forum before, during and 
after the meeting. The consensus from these discussions was basis for 
drafting this Position Paper, which was then refined by consensus 
amongst Steering Committee members. 
5. Current situation in Europe 
Information relating to the current status of post-ACS therapy with 
respect to access to LLT, procedures for intensification of therapy, lipid 
measurement, follow-up and rehabilitation were collected for all coun-
tries participating in the development of the Position Paper (Table 1) 
and are summarised below. 
5.1. Availability of drugs and reimbursement 
In most countries represented, statins are widely available, usually 
with very little or no requirement for co-payment. However, there are 
still countries in which prescribing even with co-payment is only 
possible for specific clinical indications – sometimes based on not up-to- 
date Evidence Based Medicine (EBM), and lipid-lowering drugs might be 
prescribed only by specialists. Access to ezetimibe is restricted in some 
countries (for example statin intolerance must be demonstrated), and in 
few countries prescription of ezetimibe is still limited only to selected 
specialists (cardiologists, endocrinologists). Very strict restrictions are 
still common for PCSK9 inhibitors. Many guidelines and policies require 
ezetimibe to be used, as a precondition for prescribing PCSK9 inhibitors 
therapy. In this situation, lack of access to ezetimibe effectively pre-
cludes PCSK9 therapy. 
Fig. 2. Special pathway for patients with extreme cardiovascular (CV) risk (Recurrent myocardial infarction (MI) + previous vascular event in last 2 years; Acute 
coronary syndrome (ACS) + multivessel disease (MVD); ACS + Polyvascular disease; ACS + familial hypercholesterolaemia (FH); ACS + diabetes mellitus (DM) + at 
least one additional risk factor). Consider immediate initiation of Dual lipid-lowering therapy (LLT) and intensify if necessary (IIbC). 
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5.2. Intensification of drug therapy 
Intensification of lipid-lowering therapy following discharge, is a 
common problem, particularly when primary care is responsible for this 
task. As a result, rates of achieving LDL-C target values are low, and the 
recent data clearly showed that only 18% of patients achieved LDL-C 
level of 55 mg/dl (1.4 mmol/l) [28]. The recent data also clearly 
showed that in most cases only combination therapy with statins, eze-
timibe and PCSK9 inhibitors might allow to be on target for most pa-
tients at very high and extremely high cardiovascular risk [29]. A variety 
of reasons were provided for the failure to intensify statin therapy – 
many of which fell under the heading of ‘therapeutic inertia’. Some 
countries reported a very hostile anti-statin movement in public media, 
a problem which has been observed elsewhere [30]. Unusual and 
non-evidence-based practices by GPs (such as regularly reducing the 
statin doses or recommending an annual ‘statin holiday’) were also re-
ported. Statins are strongly susceptible to the ‘drucebo effect’, whereby 
the expectation of adverse effects (particularly muscle pain), rather than 
the pharmacological effect of the drug causes the patients to experience 
adverse effects [31–33]. In light of this, it was reported that some pri-
mary care physicians (but also cardiologists and other specialists) pre-
scribe lower doses of statin then indicated, because they believe that this 
will reduce the adverse effects, and they fear that any adverse effect will 
lead to treatment cessation. In situations of polypharmacy, it was 
reported that patients and doctors often prioritised the use of other 
medicines for CVD over statins. There is also a phenomenon called 
‘deprescription’ of statins, especially observed in geriatrics patients. 
Another issue, that needs to be at least briefly mentioned is statin 
loading before, during or after vascular interventions. One should 
remember that high-dose statin pretreatment is recommended for PCI 
and CABG according to current guidelines, and statin discontinuation 
should be avoided during acute CV events and vascular interventions 
[34]. 
5.3. Lipid measurement and reference values 
It was apparent that universal measurement of plasma lipids on 
admission to hospital is not a routine practice in all countries. The ele-
ments of the lipid report varied in their complexity. In several countries, 
a problem arose from a mismatch between the laboratory definition of 
’normal’ values with a patient’ target values according to the guidelines 
and based upon their risk profile. This was believed to contribute to 
reduced motivation to increase LLT dosage and even treatment cessation 
in patients who consequently thought that LLT was no longer necessary. 
5.4. Follow-up and cardiac rehabilitation 
Common problems were identified with respect to the availability of, 
Fig. 3. Special pathway for participants with objectively confirmed complete statin intolerance. Initiate ezetimibe monotherapy and intensify if necessary.  
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Fig. 4. Special pathway: Patients already taking statin therapy and ezetimibe for at least 8 weeks prior to admission, statin therapy should be intensified if possible, 
and immediate treatment with a PCSK9i should be considered. 
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and patients’ engagement in cardiac rehabilitation programmes. In 
Poland, the KOS (comprehensive care programme for ACS patients) [35, 
36] had relatively good results (still needs to be optimized, especially 
concerning LDL-C regular monitoring), but similar services are not 
universally available in all countries. There was significant variability in 
the extent to which interventional cardiologists were involved in 
follow-up coordinated care. This highlighted the need for a standardised 
pathway for acute therapy and discharge and pointed out that objective 
quality control measures were required to evaluate rehabilitation 
services. 
6. Recommendations 
The recommendations for optimal LLT in ACS are presented below, 
as a main treatment pathway, with additional pathways for a small 
number of specific clinical practice scenarios. The pathways are based 
upon the principles of LDL-C reduction: The earlier the better, the lower the 
better, the longer the better [17]. The pathways are also firmly based in 
the /EAS guidelines for the management of dyslipidaemias [15], albeit 
with a greater emphasis on reducing delays in lipid-lowering, particu-
larly in those individuals at the greatest risk of recurrent events. 
The main pathway for optimal LLT post ACS can be divided into 3 
sections (Fig. 1):  
• Diagnosis and stratification  
• Target-driven LLT  
• Support and follow-up 
In the diagnosis and stratification stage, some patient groups are 
identified for special pathways. These include patients with familial 
hypercholesterolaemia (FH) (either heterozygous (HeFH), or homozy-
gous (HoFH)) or extremely high ASCVD risk (Section 6.1.1; Fig. 2), 
statin intolerance (Section 6.1.2; Fig. 3) and those who have LDL- 
C > 120 mg/dl (3.0 mmol/l) despite at least 8 weeks of combination 
therapy with high-intensity statin and ezetimibe (Section 6.1.3; Fig. 4). 
All other patients can be managed by a three-stage target-driven 
approach to LLT. In statin-treated patients with LDL < 100 mg/dl 
(2.5 mmol/l), statin therapy has to be intensified to maximally tolerated 
dose. In statin naïve patients with LDL-C < 120 mg/dl (3.0 mmol/l), 
therapy with high doses of atorvastatin or rosuvastatin should be 
commenced. In each case a reduction of LDL-C by 50% (target <55 mg/ 
dl [1.4 mmol/l]) is aimed for. In statin treated patients with LDL-C 
100–300 mg/dl (2.5–7.5 mmol/l), or statin naïve patients with LDL-C 
120–300 mg/dl (3–7.5 mmol/l), maximally tolerated statin therapy 
should be combined with ezetimibe, to obtain a 50–80% reduction in 
LDL-C (target <55 mg/dl [1.4 mmol/l]). In any patient with LDL- 
C > 300 mg/dl (7.5 mmol/l) on admission, > 80% reduction in LDL-C is 
required to reach the target of < 55 mg/dl (1.4 mmol/l). Therefore, 
triple therapy (statin + ezetimibe + PCSK9 inhibitor) might be initiated 
in hospital. All patients should be followed-up after 4–6 weeks, and 
treatment should be intensified if necessary (or if it has not been already 
intensified) to reach the target. Once the LDL-C target (<55 mg/dl 
[1.4 mmol/l]) has been achieved, less frequent follow-up is acceptable. 
In case of ineffectiveness of such a treatment the patient should be 
referred to a lipidologist. 
6.1. Special pathways 
The diagnosis and stratification stage identifies groups of patients 
who need care which differs from the standard pathway. Advice relating 
to these groups is provided below. 
6.1.1. Extreme cardiovascular risk 
The current ESC/EAS dyslipidaemia guidelines (2019) include all 
ACS patients to a ‘very high risk’ category. However, these guidelines 
are incomplete concerning the definition of extremely high-risk patients. 
Based upon recent statements made by ILEP [37], and the joint recom-
mendations of the Polish Society of Laboratory Diagnostics (PSLD) and 
the Polish Lipid Association (PoLA) [38], the following definition of 
‘extremely high risk’ is proposed (based on the numerous data from 
trials with PCSK9 inhibitors) [6,7,39]. 
Patients fulfilling any of the following criteria (not being on the LDL- 
C target despite intensive/maximally tolerated statin therapy and eze-
timibe) should be considered to be at ‘extremely-high’ risk:  
• Recurrent MI + previous vascular event in the last 2 years  
• ACS + multivessel disease (MVD)  
• ACS + polyvascular disease  
• ACS + familial hypercholesterolaemia (FH)  
• ACS + diabetes mellitus (DM) + at least one additional risk factor 
(including hsCRP ≥3 mg/L and/or chronic kidney disease with eGFR 
< 60 ml/min/1.73 m2 and/or lipoprotein(a) > 50 mg/dl). 
The extremely high-risk nature of this group demands a lower target 
for LDL-C (< 40 mg/dl [1 mmol/l]). In order to minimise delay to 
achieve this lipid target in these individuals and bearing in mind the 
potential difficulties in attaining the lower target, initial immediate dual 
therapy should be considered, using maximally-tolerated statin therapy 
and ezetimibe. A PCSK9 inhibitor can be prescribed at follow-up if the 
target is not met (Fig. 2). Taking into account the limited data con-
cerning the group of extremely high-risk patients (based on the sub-
group analyses), the prospective validation of these groups is still 
necessary. 
6.1.2. Statin intolerance 
If complete statin intolerance has been confirmed using objective 
criteria (it refers usually only to 3–5% of patients with statin therapy) 
[40–42] the treatment should proceed immediately using non-statin LLT 
(Fig. 3). In the case of partial statin intolerance, the main pathway 
(Fig. 1) allows for combination therapy with a maximally tolerated 
statin dose and additional LLTs. In this situation, consideration should 
be given to early initiation of additional LLTs in combination with a low 
dose of statin, rather than delaying target attainment by slow gradual 
upward titration of the statin dose. Such an approach allows to reduce 
the risk of LDL-C visit to visit variability and significant increase of 
recurrent CVD events [43,44]. 
6.1.3. Patients on maximal statin and ezetimibe therapy 
In accordance with the (Class IIa) recommendation of the ESC/EAS 
Table 2 
Suggested wording of a discharge letter of a post-ACS patient (modified based on 
the recommendations of the Czech Acute Cardiac Care Association [45]).   
• Follow-up with a GP within 7 days after discharge.  
• Follow-up with a cardiologist; first follow-up after discharge within 4 weeks after 
discharge.  
• Healthy lifestyle, regular adequate physical activity according to tolerance and 
concomitant conditions, heart-healthy diet, no smoking (!), regular check-ups of 
blood pressure and lipid levels (1st after 4–6 weeks, 2nd after 8–12 weeks, 3rd after 
6 months, 4th after 12 months, forthcoming check-ups depending on the targets 
achievements – at least once a year).  
• Dual antiplatelet therapy for 12 months.  
• Monitoring of liver (especially in case of symptoms) and renal tests, glycaemia, 
creatine kinase in 4–6 weeks.  
• Intensive/maximally tolerated statin treatment (maximum dose of atorvastatin or 
rosuvastatin preferably), check of plasma lipid levels in 4–6 weeks with adjustment 
of lipid lowering treatment to meet the LDL-C goal that is set at < 55 mg/dl/40 mg/ 
dl (1.4 mmol/L/1.0 mmol/L).  
• If the abovementioned target LDL-C level AND at the same time a reduction of at 
least 50% (compared to the baseline value) cannot be reached, the patient should be 
offered treatment with a PCSK9 inhibitors.  
• Risk factor control, goal attainment and patients’ adherence to therapies must be 
regularly checked (also with e-visits/e-advises), at least once monthly during the 
first 3 month and then in 3–6 months periods.  
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dyslipidaemia guidelines, in ACS patients who have not attained LDL-C 
target levels despite taking a maximally tolerated statin dose and eze-
timibe in pre-hospital period, consideration should be given to the 
initiation of PCSK9 inhibitor therapy during hospitalisation [15]. 
6.2. Support and follow-up 
Particular consideration should be given to communication at the 
interface of secondary and primary care, with the aim of maximising 
adherence to the treatment pathway, follow-up and escalation of LLT. A 
standardised discharge letter should be used for all patients. It is 
particularly important to include personal LDL-C goals and specific in-
structions about how and when treatment should be escalated if treat-
ment targets are not achieved. Furthermore, the letter should describe 
the process of regular monitoring (including tele-monitoring, e-visits, e- 
advice, e-prescriptions, e-referrals). An example of such a discharge 
letter content is presented in the Table 2. 
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Járai has served as a consultant for and received honoraria from Bayer, 
Berlin-Chemie, Boehringer-Ingelheim, Egis, KRKA, MSD, Mylan, 
Novartis (Sandoz), Pfizer, Richter Gedeon, Sanofi, Servier, Teva; Dr. 
Magda has received consultations fee from Novartis, Sanofi and Servier; 
Dr. Margetic has received a fee for scientific activities from Novartis and 
Sanofi; Dr. Ostadal has received honoraria from Amgen, Astra Zeneca, 
Edwards, Getinge, Medtronic, Novartis and Sanofi; Dr. Pella has received 
grant support and honoraria from Sanofi, Amgen, MSD, Servier, 
Novartis and Pfizer; Dr. Trbusic has received a fee for scientific activities 
from Novartis and Sanofi; Dr. Udroiu has received fee for scientific ac-
tivities from Astra Zeneca and Pfizer; Dr. Vlachopoulos has received 
grants and fees for scientific activities from Amgen, Sanofi and MSD; Dr. 
Vulic has received a fee for scientific activities from Sanofi; Dr. Fras has 
received grants and fees for scientific activities from Amgen, Astra 
Zeneca, Bayer, Boehringer-Ingelheim, Krka Pharma, Mylan, Novartis, 
Pfizer and Sanofi; Dr. Reiner received honoraria from Sanofi and 
Novartis. All other authors have nothing to declare. 
References 
[1] G.A. Roth, G.A. Mensah, C.O. Johnson, G. Addolorato, E. Ammirati, L.M. Baddour, 
N.C. Barengo, A.Z. Beaton, E.J. Benjamin, C.P. Benziger, A. Bonny, M. Brauer, 
M. Brodmann, T.J. Cahill, J. Carapetis, A.L. Catapano, S.S. Chugh, L.T. Cooper, 
J. Coresh, M. Criqui, N. DeCleene, K.A. Eagle, S. Emmons-Bell, V.L. Feigin, 
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S. Kownator, J. Constans, J.F. Renucci, P.G. Steg, N. Chakfe, M. Farnier, F. Bocarra, 
I. Gouni-Berthold, G. Faulmann, F. Schaper, B. Manfras, A. Schäfer, N. Weiss, 
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J. Jóźwiak, G. Gajos, M. Lukaszewicz, J.D. Kasprzak, M. Banach, S. Kasperczyk, 
J. Krawczyk, M. Lukaszewicz, D. Gaita, A. Cerghizan, N. Pletea, M.I. Popescu, 
I. Donoiu, I. Ionescu, K. Raslova, B. Raska, P. Bojcik, L. Masana, J. Masjuán-Vallejo, 
E. Jodar, F. Gomez-Delgado, F.J. Tinahones, EU-wide cross-sectional observational 
study of lipid-modifying therapy use in secondary and primary care: the DA VINCI 
study, Eur. J. Prev. Cardiol. (2020), https://doi.org/10.1093/eurjpc/zwaa047. 
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A. Wojdyła-Hordyńska, R. Bryk, P. Jankowski, M. Gąsior, Comprehensive 
coordinated care after myocardial infarction (KOSZawal): a patient’s perspective, 
Kardiol. Pol. 77 (2019) 568–570. 
[36] K. Wita, A. Kułach, M. Wita, M. Wybraniec, K. Wilkosz, M. Polak, M. Matla, 
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